top of page
About Us
Aravax is a clinical-stage biotechnology company developing the first safe, convenient and disease-modifying treatment for peanut allergy.
Aravax uses proprietary platform technology to precisely reset the immune system to tolerate allergens, without provoking severe reactions during treatment
Clinical Trials
Phase 1 clinical trials (AVX-001 and AVX-001-EXT) of PVX108 have been successfully completed.
Phase 2 trials (AVX-201) have now commenced in Australia, and preparations are underway to open trial centres in the United States.
bottom of page